Stock Ticker

  • Loading stock data...

Celsion Corporation (NASDAQ:CLSN) Announces Translational Data From OVATION Study In Latest Diagnosed Advanced Ovarian Cancer Patients

Celsion Corporation (NASDAQ:CLSN) has recently announced the latest translational data from the OVATION study of the Phase 1b dose clinical trials that combined GEN-1, Company’s 1L-12 gene-mediated immunotherapy, together with standard care for treatment of the lately-diagnosed patients of Stage 3 and 4 ovarian cancer. The patients went through the neoadjuvant chemotherapy (NACT) and afterwards […]

Sign Up To Get Our Latest Stocks Alerts